Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 +2.99%
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($0.50), $0.43 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $500.92 million versus the consensus estimate of $532.36 million.
The company reiterated 2024 financial guidance, including combined Net Product revenues of $1,575 million to $1,650 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- Rocket Lab launches U.S. Space Force mission in record 16 hours
- JPMorgan Starts BSE Limited (BSE:IN) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
